Publications by authors named "Stan Kaye"

Claim this Profile
A
A radiomics-based decision support tool improves lung cancer diagnosis in combination with the Herder score in large lung nodules.
Benjamin Hunter, Mitchell Chen, Prashanthi Ratnakumar, Esubalew Alemu, Andrew Logan, Stan Kaye

EBioMedicine· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer.
Michal M Hoppe, Patrick Jaynes, Joanna D Wardyn, Sai Srinivas Upadhyayula, Tuan Zea Tan, Stan B Kaye

EMBO Mol Med· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK - A16037).
Susana Banerjee, Holly Tovey, Rebecca Bowen, Elizabeth Folkerd, Lucy Kilburn, Stan Kaye

Ther Adv Med Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline Results of the West London lung cancer screening pilot study - Impact of mobile scanners and dual risk model utilisation.
Emily C Bartlett, Samuel V Kemp, Carole A Ridge, Sujal R Desai, Saeed Mirsadraee, Stan B Kaye

Lung Cancer· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.
Robin L Jones, Mark J Ratain, Peter J O'Dwyer, Lillian L Siu, Jacek Jassem, Stan B Kaye

Eur J Cancer· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics services.
Cathryn A Moss, Elena Cojocaru, Janet Hanwell, Simon Ward, Wen Xu, Stan B Kaye

Eur J Cancer· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials.
Raghav Sundar, Terri McVeigh, David Dolling, Ann Petruckevitch, Nikolaos Diamantis, Stan B Kaye

Eur J Cancer· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials.
Terri Patricia McVeigh, Raghav Sundar, Nikolaos Diamantis, Stan B Kaye, Udai Banerji

Eur J Cancer· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors.
Malaka Ameratunga, Maxime Chénard-Poirier, Irene Moreno Candilejo, Manuel Pedregal, Andrew Lui, Stan Kaye

Eur J Cancer· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy.
Raquel Perez-Lopez, Desam Roda, Begona Jimenez, Jessica Brown, Joaquin Mateo, Stan B Kaye

Oncotarget· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNAi screen reveals synthetic lethality between cyclin G-associated kinase and FBXW7 by inducing aberrant mitoses.
Saoirse O Dolly, Mark D Gurden, Konstantinos Drosopoulos, Paul Clarke, Johann de Bono, Stan Kaye

Br J Cancer· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?
Marta Capelan, Desamparados Roda, Elena Geuna, Karim Rihawi, Shankar Bodla, Stan B Kaye

Lung Cancer· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
Stephanie Lheureux, Zhongwu Lai, Brian A Dougherty, Sarah Runswick, Darren R Hodgson, Stan Kaye

Clin Cancer Res· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Saeed Rafii, Charlie Gourley, Rajiv Kumar, Elena Geuna, Joo Ern Ang, Stan B Kaye

Oncotarget· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib and somatic BRCA mutations.
Angela George, Susana Banerjee, Stan Kaye

Oncotarget· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline Mutations and Selected Sporadic Cancers.
Johann de Bono, Ramesh K Ramanathan, Lida Mina, Rashmi Chugh, John Glaspy, Stan Kaye

Cancer Discov· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole.
Angela George, Jennifer McLachlan, Nina Tunariu, Chiara Della Pepa, Cristina Migali, Stan Kaye

BMC Cancer· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.
Angela George, Stan Kaye, Susana Banerjee

Nat Rev Clin Oncol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.
Angela George, Rebecca Kristeleit, Saeed Rafii, Caroline O Michie, Rebecca Bowen, Stan B Kaye

Eur J Cancer· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A study of motivations and expectations of patients seen in phase 1 oncology clinics.
Saoirse O Dolly, Eleftheria Kalaitzaki, Martina Puglisi, Sarah Stimpson, Janet Hanwell, Stan Kaye

Cancer· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trabectedin as a chemotherapy option for patients with BRCA deficiency.
Bradley J Monk, Domenica Lorusso, Antoine Italiano, Stan B Kaye, Miguel Aracil

Cancer Treat Rev· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation.
Joo Ern Ang, Rupinder Pandher, Joo Chew Ang, Yasmin J Asad, Alan T Henley, Stan B Kaye

Mol Cancer Ther· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies.
Joaquin Mateo, David Olmos, Herlinde Dumez, Srinivasu Poondru, Nancy L Samberg, Stan B Kaye

Br J Cancer· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARP inhibitors: the race is on.
Jessica S Brown, Stan B Kaye, Timothy A Yap

Br J Cancer· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.
Jonathan A Ledermann, Andrew C Embleton, Fharat Raja, Timothy J Perren, Gordon C Jayson, Stan B Kaye

Lancet· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis